{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T04:42:56Z","timestamp":1771562576619,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.ijpharm.2017.03.079","type":"journal-article","created":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T15:15:22Z","timestamp":1491059722000},"page":"463-469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Clarithromycin and N -acetylcysteine co-spray-dried powders for pulmonary drug delivery: A focus on drug solubility"],"prefix":"10.1016","volume":"533","author":[{"given":"Michele Dario","family":"Manniello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Del Gaudio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita P.","family":"Aquino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2017.03.079_bib0005","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1128\/AAC.00235-13","article-title":"Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors","volume":"57","author":"Alhajlan","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0010","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ijpharm.2012.01.026","article-title":"Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells","volume":"426","author":"Aquino","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0015","first-page":"838410","article-title":"Nanospray drying as a novel technique for the manufacturing of inhalable NSAID powders","volume":"2014","author":"Aquino","year":"2014","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0020","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ejpb.2014.02.010","article-title":"Novel co-axial prilling technique for the development of core-shell particles as delayed drug delivery systems","volume":"87","author":"Del Gaudio","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0025","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1007\/s11095-015-1745-8","article-title":"Inhalable clarithromycin microparticles for treatment of respiratory infections","volume":"32","author":"Dimer","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0030","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejphar.2015.06.051","article-title":"Hyper-osmolarity and calcium chelation: effects on cystic fibrosis mucus","volume":"764","author":"Ermund","year":"2015","journal-title":"Eur. J. Pharmacol."},{"issue":"Suppl. 2","key":"10.1016\/j.ijpharm.2017.03.079_bib0035","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0954-6111(11)70024-5","article-title":"Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis","volume":"105","author":"Geller","year":"2011","journal-title":"Respir. Med."},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0040","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/jamp.2010.0855","article-title":"Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere technology","volume":"24","author":"Geller","year":"2011","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0045","first-page":"1068","article-title":"The inhalation ad hoc advisory panel for the USP performance tests of inhalation dosage forms","author":"Gray","year":"2008","journal-title":"Pharm. Forum"},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0050","series-title":"AAPS\/FDA\/USP Workshop","article-title":"Scope and relevance of a pulmonary biopharmaceutical classification system","author":"Hastedt","year":"2015"},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0055","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.2147\/DDDT.S116443","article-title":"Development of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach","volume":"10","author":"Karimi","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0060","doi-asserted-by":"crossref","first-page":"a009589","DOI":"10.1101\/cshperspect.a009589","article-title":"CFTR, mucins, and mucus obstruction in cystic fibrosis","volume":"2","author":"Kreda","year":"2012","journal-title":"Cold Spring Harbor Perspect. Med."},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2016.04.009","article-title":"Aerodynamic properties, solubility and in vitro antibacterial efficacy of dry powders prepared by spray drying: clarithromycin versus its hydrochloride salt","volume":"104","author":"Manniello","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0070","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ijpharm.2016.09.034","article-title":"Investigation of the enhanced antimicrobial activity of combination dry powder inhaler formulations of lactoferrin","volume":"514","author":"Marshall","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0075","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2147\/COPD.S681","article-title":"Role of macrolide therapy in chronic obstructive pulmonary disease","volume":"3","author":"Martinez","year":"2008","journal-title":"Int. J. Chron. Obstr. Pulm. Dis."},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0080","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1007\/s11095-012-0744-2","article-title":"Dissolution techniques for in vitro testing of dry powders for inhalation","volume":"29","author":"May","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0085","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1007\/s11095-014-1413-4","article-title":"Dissolution testing of powders for inhalation: influence of particle deposition and modeling of dissolution profiles","volume":"31","author":"May","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0090","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1469-0691.1997.tb00279.x","article-title":"Influence of macrolides on mucoid alginate biosynthetic enzyme from Pseudomonas aeruginosa","volume":"3","author":"Nagino","year":"1997","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0095","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ejps.2014.09.017","article-title":"Redispersible liposomal-N-acetylcysteine powder for pulmonary administration: development, in vitro characterization and antioxidant activity","volume":"65","author":"Ourique","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0100","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0301-0104(97)00337-6","article-title":"Spectroscopic study of N-acetylcysteine and N-acetylcystine hydrogen peroxide complexation","volume":"228","author":"Picquart","year":"1998","journal-title":"Chem. Phys."},{"issue":"April","key":"10.1016\/j.ijpharm.2017.03.079_bib0105","first-page":"1","article-title":"Impact of capsule selection on formulation stability in dry powder inhalers (DPIs)","volume":"2011","author":"Richardson","year":"2011","journal-title":"Inhal. Mag."},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0110","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/ppul.10079","article-title":"Mucociliary clearance in cystic fibrosis","volume":"33","author":"Robinson","year":"2002","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0115","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1152\/physrev.00010.2005","article-title":"Respiratory tract mucin genes and mucin glycoproteins in health and disease","volume":"86","author":"Rose","year":"2006","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0120","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ijpharm.2012.05.077","article-title":"Gentamicin and leucine inhalable powder: what about antipseudomonal activity and permeation through cystic fibrosis mucus?","volume":"440","author":"Russo","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0125","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ejpb.2008.10.007","article-title":"Physical characteristics and aerosol performance of naringin dry powders for pulmonary delivery prepared by spray-drying","volume":"72","author":"Sansone","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0130","first-page":"297","article-title":"Macrolide antibiotic therapy in patients with cystic fibrosis","volume":"133","author":"Schoni","year":"2003","journal-title":"Swiss Med. Wkly."},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0135","first-page":"587","article-title":"Dissolution rate enhancement of clarithromycin using ternary ground mixtures: nanocrystal formation","volume":"12","author":"Shahbaziniaz","year":"2013","journal-title":"Iran. J. Pharm. Res."},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0140","first-page":"CD002203","article-title":"Macrolide antibiotics for cystic fibrosis","volume":"11","author":"Southern","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0145","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ijpharm.2013.03.030","article-title":"Non-steroidal anti-inflammatory drug for pulmonary administration: design and investigation of ketoprofen lysinate fine dry powders","volume":"448","author":"Stigliani","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0150","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/jamp.2015.1228","article-title":"Rheological properties of cystic fibrosis bronchial secretion and in vitro drug permeation study: the effect of sodium bicarbonate","volume":"29","author":"Stigliani","year":"2016","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0155","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1038\/psp.2013.76","article-title":"Population pharmacokinetics of inhaled tobramycin powder in cystic fibrosis patients","volume":"3","author":"Ting","year":"2014","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0160","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s11095-007-9475-1","article-title":"Pharmaceutical particle engineering via spray drying","volume":"25","author":"Vehring","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0165","doi-asserted-by":"crossref","first-page":"62S","DOI":"10.1378\/chest.125.2_suppl.62S","article-title":"Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa","volume":"125","author":"Wozniak","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.ijpharm.2017.03.079_bib0170","doi-asserted-by":"crossref","first-page":"276ra227","DOI":"10.1126\/scitranslmed.3010525","article-title":"Oxidation increases mucin polymer cross-links to stiffen airway mucus gels","volume":"7","author":"Yuan","year":"2015","journal-title":"Sci. Transl. Med."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517317302661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517317302661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T02:23:56Z","timestamp":1535941436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517317302661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0378517317302661"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2017.03.079","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clarithromycin and N-acetylcysteine co-spray-dried powders for pulmonary drug delivery: A focus on drug solubility","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpharm.2017.03.079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}